Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast
Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-line standard of care), the RA drug market boasts a variety of targeted agents from many drug classes, all largely competing for shares of the TNF-refractory population. The continued launch of biosimilars across the major markets will make the crowded therapy market more competitive. Increasing safety concerns about the JAK inhibitor class have pushed use of these agents to follow use of TNF-α inhibitors, primarily impacting the uptake of Xeljanz in the G7 markets. Although the late-phase pipeline is relatively sparse, the sheer number of biologics and targeted oral therapies available for RA ensures that marketers face fierce competition and increasing challenges to gain and maintain market share.
Questions answered
- What are physicians’ preferred TNF-α inhibitors, and what factors influence this perception? Given the increasingly fragmented RA market, how likely are physicians to cycle through multiple anti-TNF agents before progressing to a novel mechanism of action?
- What are physicians’ perceptions of the currently marketed non-TNF-α inhibitor biologics and oral JAK inhibitors, and where do these agents fit in their current treatment approach? Which of these agents have been and will continue to be the most successful in targeting the TNF-refractory patient segment? How have the new safety warnings regarding JAK inhibitors affected physicians’ prescribing of these agents in the RA treatment algorithm?
- How will the entry of additional novel oral therapies affect the RA treatment algorithm? In which patient segments and treatment lines will these therapies most likely be used? How will biosimilars affect sales and patient share of current RA agents and the uptake of emerging therapies?
Content highlights
Markets covered: United States, EU5, Japan
Primary research: 24 country-specific interviews with thought-leading rheumatologists
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA by country; number of diagnosed prevalent cases of RA by severity
Emerging therapies: Phase 3/PR: 1 drug; Phase 2: 7 drugs; coverage of select early-phase products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Rheumatoid Arthritis - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for rheumatoid arthritis
- Current treatments used for rheumatoid arthritis
- Market events impacting the use of key current therapies in rheumatoid arthritis
- TNF-alpha inhibitors
- Selective costimulation modulators
- B-cell-targeted therapies
- Interleukin-6 inhibitors
- Janus kinase inhibitors
- RANKL inhibitors
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Girdhari Roy, Ph.D., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Prior to joining Clarivate, Dr. Roy was a product selection and ideation scientist at Dr. Reddy’s Laboratory. He also worked as a drug metabolism and pharmacokinetics scientist at ADTL Hyderabad. He holds bachelor’s and master’s degrees in pharmacy and a doctorate in pharmaceutical sciences from BITS Pilani, Hyderabad Campus, India.
Aishwarya S. Ambat, M.P.H., Epidemiologist , Epidemiology. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.